Pyrimidines as kinase inhibitors

Details for Australian Patent Application No. 2009203693 (hide)

Owner Novartis AG

Inventors Hunt, Peter; Leblanc, Catherine; Pulz, Robert Alexander; Stiefl, Nikolaus Johannes

Agent Davies Collison Cave

Pub. Number AU-B-2009203693

PCT Pub. Number WO2009/087224

Priority 08150194.2 11.01.08 EP; 08157985.6 10.06.08 EP

Filing date 9 January 2009

Wipo publication date 16 July 2009

Acceptance publication date 7 June 2012

International Classifications

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61P 19/10 (2006.01) Drugs for skeletal disorders

Event Publications

22 July 2010 PCT application entered the National Phase

  PCT publication WO2009/087224 Priority application(s): WO2009/087224

7 June 2012 Application Accepted

  Published as AU-B-2009203693

4 October 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009203694-Pyrrolopyrimidines and Pyrrolopyridines

2009203688-Assay and method for the assessment of responders and non-responders to NK cell modulation by immunoglobulin therapy